A pharmaceutical composition comprising 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2H)-one which inhibits at least one phosphodiesterase 10 is described for treating various CNS disorders by administering such compounds to a patient in need thereof.